Prevalence of Sarcopenia in Stroke Patients (NCT07492849) | Clinical Trial Compass
CompletedNot Applicable
Prevalence of Sarcopenia in Stroke Patients
Taiwan80 participantsStarted 2025-05-05
Plain-language summary
The goal of this observational study is to analyze the characteristics of sarcopenia-related variables in post-acute and chronic stroke patients using various clinical measurement tools. The study also aims to examine the differences in these variables based on age groups (40-65 years and \>65 years), sex, and stroke severity.
The main questions it aims to answer are:
What are the differences in sarcopenia prevalence and related indicators between post-acute care and chronic stroke patients? How do age, sex, and stroke severity affect these sarcopenia-related measurements?
Participants will include stroke patients aged 40 and older with adequate cognitive and physical function to complete sarcopenia screening and questionnaires. They will be divided into two groups:
Group 1: Chronic stroke patients (n ≥ 75) Group 2: Post-acute care stroke patients (n ≥ 25)
All participants will undergo both objective and subjective assessments, including:
Objective assessments: Body composition, quadriceps strength, quadriceps and gastrocnemius muscle thickness via ultrasound, calf circumference, dominant hand grip strength, walking speed, SARC-F questionnaire, and the Mini Nutritional Assessment.
Subjective assessment: EQ-5D health-related quality of life questionnaire. The collected data will be analyzed to compare the prevalence and characteristics of sarcopenia between the two stroke groups and across different subgroups by age and sex.
Who can participate
Age range40 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Both ischemic and hemorrhagic strokes are included. 1.1 Definition of chronic stroke patients (Group 1): Patients whose last stroke occurred more than one year prior.
✓.2 Definition of post-acute care (PAC) stroke patients (Group 2): Patients whose last stroke occurred at least 14 days prior, have been assessed by a neurologist as eligible for transfer to the PAC program, and are admitted to a PAC ward.
✓. Patients with sufficient cognitive and physical ability to complete sarcopenia-related assessments (e.g., body composition, grip strength, walking speed) and the Mini Nutritional Assessment, as judged by the principal investigator.
✓. Patients who provide informed consent after being fully informed. 3.1 Group 1 (chronic stroke patients): Consent must be obtained directly from the patient.
✓.2 Group 2 (PAC stroke patients): If the patient has cognitive impairment during the PAC phase, consent may be obtained from a family member or legal representative after they have been fully informed. -
Exclusion criteria
✕. Patients with lower limb neurological, muscular, or skeletal injuries or disorders within six months prior to enrollment.
What they're measuring
1
Appendicular Skeletal Muscle Mass Index
Timeframe: at enrollment
2
Handgrip strength
Timeframe: at enrollment
3
Gait speed
Timeframe: at enrollment
Trial details
NCT IDNCT07492849
SponsorCishan Hospital, Ministry of Health and Welfare
. Patients with severe cardiopulmonary diseases or other neurological conditions requiring oxygen therapy.
✕. Patients who, within one month prior to the study, have experienced major infections requiring hospitalization and antibiotic administration or other major illnesses requiring invasive treatment (e.g., cardiac catheterization). -